Bayer's Missouri Glyphosate Test Case Lands as Pipeline Wins and a Soft Quarter Collide

Bayer shares slid 2.7% to EUR 47.75 as a fresh US glyphosate trial began, with Q3 results due November 3 and a Deutsche Bank Buy rating intact.

Bayer shares ran into a wall of selling on Wednesday, sliding 2.7% to close at EUR 47.75 as a fresh glyphosate trial in the United States reopened one of the company's most stubborn legal wounds. The decline played out against a broadly weak tape, with sticky eurozone inflation, climbing oil prices and rising bond yields dragging the DAX deep into the red and leaving little room for stock-specific optimism.

The proceeding now underway in Missouri targets Monsanto, Bayer's US subsidiary. Three plaintiffs allege the company failed to adequately test the herbicide Roundup before bringing it to market — a line of attack that diverges sharply from the warning-label claims that have defined earlier litigation. Legal observers therefore view the case as a bellwether that could reshape the scope of future liability, a framing echoed by the Süddeutsche Zeitung, which called the trial potentially pivotal for the group.

A Quarter That Looks Lighter Than It Is

Attention is now turning to how much cushion Bayer's underlying business can provide. Deutsche Bank Research kept its "Buy" rating and EUR 60 price target on Tuesday, with analyst Virginie Boucher-Ferte sketching a subdued third quarter. She projects operating sales growth of 1.3% year over year, but a 10% drop in operating profit. The earnings dip traces back largely to favorable one-off effects in the agricultural business that flattered the prior-year quarter, rather than to any collapse in demand. Even so, the figures underscore the persistent strain on the group's earning power as legal costs and broader market conditions test management.

Whether core profitability is strong enough to absorb ongoing legal uncertainty is the real litmus test for the valuation. Investors must weigh if structural margins in the key businesses can generate enough of a buffer to fund potential settlements.

Pipeline Momentum Cuts the Other Way

On the positive side of the ledger, Bayer notched meaningful regulatory progress. The FDA granted priority review on Monday to Lynkuet (elinzanetant), a hopeful asset aimed at moderate-to-severe vasomotor symptoms in women undergoing endocrine therapy for hormone receptor-positive breast cancer. That accelerated pathway shortens the road to a potential launch.

BlueRock Therapeutics, a Bayer subsidiary, added further tailwind: its cell therapy candidate Lemiretprocel picked up orphan-drug status from the FDA on Wednesday for retinitis pigmentosa and cone-rod dystrophy, alongside a matching designation from the EMA for certain inherited retinal diseases. Such statuses carry expanded market and development privileges.

The company also moved to shore up financial flexibility, placing hybrid bonds on September 23. Deutsche Bank Research reaffirmed its buy call and EUR 60 target in that context.

Portfolio Surgery Continues

Bayer's reshaping of its portfolio took another step on September 21, when the group announced the sale of cancer drug Stivarga to Grünenthal. The buyer put the potential purchase price at up to EUR 375 million, with closing expected in late 2026 or early 2027.

Institutional investors, meanwhile, are treading carefully. A voting-rights filing on Tuesday showed asset manager Amundi trimming its Bayer stake, with its holding falling from 3.04% to 2.90% after crossing a threshold on September 23. Further retreat by institutional capital could weigh on the share price even if operating data hold up. The macroeconomic backdrop for cyclical agrochemical products remains fragile as well: higher interest rates make refinancing more expensive, while volatile end markets squeeze margins.

Chart Levels and the November Print

Technically, the picture stays constructive as long as the stock avoids a decisive break below key trend lines. At EUR 47.75, the shares sit comfortably above their 200-day moving average of EUR 43.00. Holding that level would keep the medium-term uptrend alive; a significant slip beneath it would hand the bears the upper hand.

Despite the recent consolidation, Bayer stock is still up 29% year to date. Hard numbers on the current business arrive in a matter of weeks, when the company publishes its full third-quarter report on November 3 — a release that will show whether operations can carry the story or whether the US litigation seizes the narrative once more.